Research Article
Protective Effect of Keluoxin against Diabetic Nephropathy in Type 2 Diabetic Mellitus Models
Table 4
Comparisons of LC3-l, LC3-ll, LC3-ll/LC3-l, p62, and nephrin in different groups after 8 weeks.
| | Group | N | LC3-l | LC3-ll | LC3-ll/LC3-l | p62 | Nephrin |
| | Normal | 7 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | | Model | 7 | 1.00 ± 0.22 | 1.55 ± 0.18 | 1.61 ± 0.33 | 1.58 ± 0.19 | 0.60 ± 0.08 | | Keluoxin | 7 | 0.88 ± 0.15 | 1.28 ± 0.22 | 1.17 ± 0.39 | 1.21 ± 0.21 | 0.94 ± 0.09 | | Irbesartan | 7 | 1.18 ± 0.37 | 1.30 ± 0.26 | 1.49 ± 0.29 | 1.19 ± 0.18 | 0.86 ± 0.15 |
|
|
Data were presented as means ± SD. and versus the normal group; and versus the model group. |
